NY-AQARA
13.9.2022 09:01:43 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, introduced its Radiator Thermostat E1 to automate hydronic radiators including wall-mounted radiators, towel warmers and even warm floors, making the heating systems smarter for improved energy efficiency and comfort. This radiator thermostat supports most radiator valves with its M30*1.5mm thread connection and the provided adapters for RA, RAV and RAVL valves1. The Aqara Radiator Thermostat E1 is now available on European Amazon stores (France, Germany, Italy, Spain, UK), as well as via selective Aqara retailers in Europe2.
Based on the Zigbee 3.0 protocol, the Thermostat is expected to support the future-proofing Matter standard via an OTA update of the compatible, Zigbee 3.0-based Aqara hub3. The device is also compatible with major ecosystems and voice assistants such as HomeKit/Siri, Alexa, Google Home/Google Assistant, IFTTT, Home Assistant4 and more. Users can be reassured that the Thermostat works with their smart home setups of today and tomorrow.
Unlike many thermostatic radiator valves (TRVs) that rely solely on an internal sensor to measure the room temperature, which can be inaccurate due to the sensor’s proximity to the radiator, the Radiator Thermostat E1 can receive the temperature readings directly from a connected Aqara temperature sensor5 (including in HomeKit), and regulate the radiator based on the actual room temperature to increase comfort. Moreover, when connected to an Aqara Door and Window Sensor, the Thermostat can be configured to stop heating the room when any door or window is left open, in order to reduce energy waste. With the wide range of Aqara devices, users are able to create customized home automation that heats their homes only when it’s needed.
The Aqara Home app also offers various options for radiator automation. A smart schedule can be configured, allowing users to set the desired temperatures for different periods of time throughout the day, for example to set it to 5℃ during the daytime of weekdays when no one is at home, 25℃ for a relaxing evening after work, and 20℃ for a night of comfortable sleep. Geofencing is also possible, so the radiators will heat up the home before the family arrives. Another option is to automate the radiators based on local weather, and the heating will turn on automatically when the local temperature drops below a certain threshold.
Other features of the Radiator Thermostat include:
- Device grouping: multiple radiators in one room can be synchronized so that they work in a more efficient way, and make it possible to set different temperatures for each room;
- Multi-home management: in the case of having more than one home, users are able to manage the radiators in each home separately and set up individual automation such as geofencing-based automation;
- Anti-freeze mode: users can preset a temperature between 5℃ - 15℃ for this mode, and activate the mode easily when they are out of town to conserve energy while reducing the risk of pipe freezing;
- 12-month battery life: thanks to the Zigbee protocol and the energy-efficient hardware, 2 AA batteries will power the Thermostat for up to one year of use6.
To celebrate the launch, Aqara now offers a 10% discount for the Radiator Thermostat on its European Amazon stores in France, Germany, Italy, Spain and the UK with the promo code TRVE1UKEU. The code will be valid through September 15, 2022.
For more details of the Radiator Thermostat E1, please visit our website.
- This thermostat is only compatible with thermostatic valves, while manual, return temperature limiter (RTL) as well as monotube radiator systems are not supported. However in the majority of cases, it is possible to convert the existing radiator valve to a supporting one using an aftermarket adapter. Please consult professional installers or authorized Aqara retailers for more details.
- Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the local retailer(s) for real time availability.
- Matter support may be unavailable by the time of the launch.
- Home Assistant support can be achieved using HomeKit Controller integration, which is developed by the Home Assistant community.
- Aqara’s Temperature and Humidity Sensor or TVOC Air Quality Monitor is required.
- Battery life may vary depending on the usage. The 1-year battery life is calculated based on the assumption of 8 operations per day for a heating season of 165 days and 1 operation every 2 weeks for the rest 200 days.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
